Page 16 - Michael Strapazon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amgen today announced that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Otezla ® for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act action date of December 19, 2021 . “Otezla has been prescribed to hundreds of thousands of patients with … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla ® (...

Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021. “Many people with mild-to-moderate plaque psoriasis still report … Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surfac...

Share this article THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021.  "Many people with mild-to-moderate plaque psoriasis still report challenges in managing their symptoms, which can have a significant impac...

Amgen Announces Webcast Of 2021 First Quarter Financial Results News provided by Share this article Share this article THOUSAND OAKS, Calif., April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. L...